GE HealthCare Anesthesia Systems Recall

potentially life-threatening risk in Volume Control Ventilation (VCV) mode

GE Carestation Anesthesia Systems

GE HealthCare has issued a high-priority correction for certain Carestation anesthesia systems due to a potentially life-threatening risk when used in Volume Control Ventilation (VCV) mode.

Affected Devices

  • Carestation 620, 650, 650c
  • Carestation 750, 750c

These systems are used in hospitals and surgical settings for delivering anesthesia and ventilatory support to patients of all ages.

The Problem

In VCV mode, the devices affected may fail to ventilate properly. If this happens:

  • Alarms and warnings will be triggered (e.g., bellows stop moving, “Unable to Drive Bellows” message, apnea alerts).
  • If uncorrected, this can lead to serious injury or death from hypoxia (low oxygen levels).

What to Do

GE HealthCare recommends:

  1. Do NOT use VCV mode until the device is corrected.
  2. Use only:
    • Pressure Control Ventilation (PCV)
    • Pressure Control Ventilation Volume Guarantee (PCV-VG)
    • Or manual ventilation
  3. Perform a Ventilation Screening Test on each system.
  4. Train your staff and ensure they are aware of the risk and temporary workaround.
  5. Return the Acknowledgement Form provided in the correction notice.

Questions?

Call GE HealthCare Service at 1-800-437-1171.

If your facility uses these systems, take immediate action to prevent harm. GE HealthCare is currently correcting the devices — no need to remove them from service if alternate modes are used safely.

Abbott Safety Alert for Freestyle Libre Systems

Misuse may cause battery overheating and incorrect readings The FDA has issued a safety notification regarding the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems. The notification warns users of the potential for...

Camber Recalls Atovaquone Oral Suspension USP

Camber Recalls Atovaquone Oral Suspension USP for Potential Contamination Camber Pharmaceuticals Inc. recently issued a voluntary nationwide recall of Atovaquone Oral Suspension USP due to potential contamination. The recall was announced by the U.S. Food and Drug...

Prodigy Proclaim Spinal Cord Stimulation Systems

Significant advancement for chronic pain treatment On February 15, 2023, the U.S. Food and Drug Administration (FDA) announced the approval of the Prodigy Proclaim and Proclaim XR Spinal Cord Stimulation (SCS) systems. This approval marks a significant step forward in...